


Samsung Biologics expands global footprint with new CDO R&D centre

29 October 2020 | News

The newly opened San Francisco CDO R&D Center will bridge Samsung Biologics with its biotech clients in its first step towards global expansion



Samsung Biologics has announced the grand opening of its first US CDO (Contract Development Organisation) R&D Center in San Francisco, bringing its contract development services closer to global clients.

As the "Next Door CDO Partner," the South Korea based company aims to maximize client satisfaction and provide immediate convenience to biotech companies in the Bay area.

Tapping into San Francisco, the birthplace of biotech and one of the fastest developing bioclusters, Samsung Biologics will provide real-time interaction and be in closer proximity to potential and existing clients in the region.

Aligned with the Company's mission to offer a seamless one-stop service, the new facility will utilize the same CDO research and development capabilities present at its headquarters in Incheon, South Korea.

Samsung Biologics' CDO business brings quality-driven development services at a greater speed, delivering cell line development to DS manufacturing in six months, and to DP manufacturing in seven months at the fastest pace in the industry.

Leveraging the Company's operational excellence, Samsung Biologics plans to go above and beyond by offering end-to-end service from the early stages of discovery to the final manufacturing of drug products in a shorter development time.

With its experts working "next-door," the newly opened San Francisco CDO R&D Center will bridge Samsung Biologics with its biotech clients in its first step towards global expansion in providing optimized satisfaction and even greater convenience with faster and better service offerings.